Scope

This is a purchasing and compliance overview for business readers. It does not describe how to perform any treatment, and nothing here states or implies that any product is approved or suitable for use in the UK. Regulatory status depends on the specific product, its claims and the jurisdiction, and must be verified for each product.

Two terms, different levels of precision

Dermal filler describes a recognisable product group. EU medical device law, which applies in Northern Ireland, lists among products without an intended medical purpose "substances, combinations of substances, or items intended to be used for facial or other dermal or mucous membrane filling by subcutaneous, submucous or intradermal injection or other introduction", excluding tattooing products (EU MDR, Annex XVI). English law uses a similarly broad definition. The Botulinum Toxin and Cosmetic Fillers (Children) Act 2021 defines a filler as "any substance used for dermal or mucous membrane filling (whether or not designed to be so used)" (2021 Act).

Skin booster is different. We have not found it defined in UK legislation, and it is best understood as a marketing and clinical description rather than a regulatory category. Products sold under the name vary in composition and intended purpose. The published literature includes, for example, a 2025 study that describes hyaluronic acid-based "skinboosters" as having a low rheological profile that allows even distribution throughout the dermis (Pino et al., 2025). It also includes a study of polynucleotides combined with hyaluronic acid, given by intradermal injection (Lee et al., 2024). Two products carrying the same label may therefore differ in ingredients, mechanism, evidence and regulatory route.

For a buyer, the practical rule is simple. Treat "skin booster" as a prompt to find out exactly what the product is, never as an answer.

How regulatory status is decided

A product's regulatory route depends heavily on what its manufacturer says it is for. The MHRA's borderline guidance for Great Britain explains that whether a product has a medical purpose "will be defined by the manufacturer's intention for the product as defined in their labelling, instructions for use and promotional material and its mode of action" (MHRA, borderlines). The same substance can therefore sit in different categories depending on its claims. That is why supplier marketing and product documentation deserve careful reading.

Great Britain

Medical devices in Great Britain are regulated under the Medical Devices Regulations 2002, as amended. All medical devices must be registered with the MHRA before being placed on the GB market. Manufacturers based outside the UK must appoint a UK Responsible Person, who registers their devices and whose name and address must appear on the labelling, outer packaging or instructions where applicable (MHRA, regulating devices).

Fillers marketed only for aesthetic purposes have sat awkwardly in this framework. In its 2022 response to consultation, the government said the MHRA intended to bring into scope products for which a manufacturer claims only an aesthetic or other non-medical purpose. It said this would include dermal fillers, and that they were expected to become Class III devices (government response, 2022). We have not been able to confirm from primary sources whether this change is now fully in force. Buyers should check the MHRA's current guidance rather than rely on older articles, including this one.

Northern Ireland

Under the Windsor Framework, the EU Medical Device Regulation has applied in Northern Ireland since 26 May 2021 (MHRA, regulating devices). That regulation applies to the Annex XVI product groups, including dermal filling products without a medical purpose, from the date common specifications for those groups apply (EU MDR, Article 1(2)). Marking and registration requirements in Northern Ireland differ from those in Great Britain.

Rules about who treats whom

Product rules are only half of the picture. In England, it is an offence to administer botulinum toxin, or a filler by subcutaneous, submucous or intradermal injection for a cosmetic purpose, to a person under 18. That provision came into force on 1 October 2021 (2021 Act).

A wider licensing scheme for non-surgical cosmetic procedures in England has been under development. The Health and Care Act 2022 gave the government the power to create one. The government's August 2025 consultation response proposed grading procedures as green, amber or red by risk. The highest-risk procedures would be limited to suitably qualified regulated healthcare professionals in premises regulated by the Care Quality Commission. According to the House of Commons Library's September 2025 briefing, however, there were not yet specific controls on who can offer these procedures (Commons Library). Arrangements in Scotland, Wales and Northern Ireland differ and are not covered here.

For suppliers, this matters because customers will increasingly be asked to show where products came from and who may use them.

Establishing product identity

Before discussing price or volume, pin down exactly what the product is. We suggest recording:

  • the legal manufacturer's name and address, and whether the business you are dealing with is that manufacturer, a distributor or an agent;
  • the exact product name, variant and presentation, because product families often include several formulations;
  • the composition as declared by the manufacturer, for example the type and concentration of hyaluronic acid;
  • the stated intended purpose, and the classification the manufacturer relies on;
  • the marking and registration position for the market where the product will be used, and the identity of the UK Responsible Person where one is required.

Supporting documentation and evidence

A reputable supplier should be able to provide, or direct you to, the instructions for use and labelling in English, the declaration of conformity, and any certificate issued by an approved or notified body for the product's class. They should also be able to provide a summary of the clinical evidence and safety information, and, for sterile products, information on sterility and packaging integrity.

Read clinical evidence with the same care as any other study. The hyaluronic acid skinbooster study mentioned above involved 81 volunteers at a single centre. Its authors declared that one of them is scientific director of the company that sells the product, and that several others are researchers there (Pino et al., 2025). Industry studies are normal and can be valuable, and declaring interests is good practice. But it is part of the context, alongside sample size, design and whether the product studied is identical to the one being offered.

A warning sign

Treat claims such as "approved in the UK" or "fully licensed" with caution unless they come with documents you can check, such as registration details. Be equally cautious with relabelled products and supply chains that cannot be traced back to the legal manufacturer.

Traceability and storage

Good traceability protects patients, clinics and suppliers alike. In our view, a sound supply arrangement should let you trace every unit from the legal manufacturer to the end user by batch or lot number and expiry date. It should keep storage and transport within the conditions stated in the instructions for use, with records where temperature control is specified. And it should keep delivery and dispatch records that make a recall practical.

Problems with medical devices can be reported to the MHRA through the Yellow Card scheme, which covers medicines and medical devices and accepts reports from anyone (MHRA, Yellow Card). Suppliers should have their own process for handling complaints and passing them to the manufacturer.

Questions for suppliers

  • Who is the legal manufacturer, and what is your relationship with them?
  • What exactly does the product contain, and what intended purpose does the manufacturer state?
  • What is the product's regulatory status and registration position for the market where it will be used, and can you provide evidence?
  • Who is the UK Responsible Person, if one is required?
  • Can you provide the English instructions for use, the declaration of conformity and any relevant certificates?
  • What clinical evidence exists for this exact product, and who carried it out?
  • What are the storage and transport conditions, and how are they maintained and recorded?
  • How are complaints, adverse incidents and recalls handled?

Clear, documented answers are a sign of a supplier worth continuing with. Vague answers, or reluctance to share documents, tell you something too.